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A B S T R A C T
Sudden cardiac death (SCD) represents a major cause of death
in end-stage kidney disease (ESKD). The precise estimate of its
incidence is difficult to establish because studies on the inci-
dence of SCD in ESKD are often combined with those related to
sudden cardiac arrest (SCA) occurring during a haemodialysis
(HD) session. The aim of the European Dialysis Working
Group of ERA-EDTA was to critically review the current litera-
ture examining the causes of extradialysis SCD and intradialysis
SCA in ESKD patients and potential management strategies to
reduce the incidence of such events. Extradialysis SCD and
intradialysis SCA represent different clinical situations and
should be kept distinct. Regarding the problem, numerically
less relevant, of patients affected by intradialysis SCA, some
modifiable risk factors have been identified, such as a low con-
centration of potassium and calcium in the dialysate, and some
advantages linked to the presence of automated external defib-
rillators in dialysis units have been documented. The problem
of extra-dialysis SCD is more complex. A reduced left ventricu-
lar ejection fraction associated with SCD is present only in a mi-
nority of cases occurring in HD patients. This is the proof that
SCD occurring in ESKD has different characteristics compared
with SCD occurring in patients with ischaemic heart disease
and/or heart failure and not affected by ESKD. Recent evidence
suggests that the fatal arrhythmia in this population may be due
more frequently to bradyarrhythmias than to tachyarrhythmias.
This fact may partly explain why several studies could not dem-
onstrate an advantage of implantable cardioverter defibrillators
in preventing SCD in ESKD patients. Electrolyte imbalances,
frequently present in HD patients, could explain part of the ar-
rhythmic phenomena, as suggested by the relationship between
SCD and timing of the HD session. However, the high incidence
of SCD in patients on peritoneal dialysis suggests that other risk
factors due to cardiac comorbidities and uraemia per se may
contribute to sudden mortality in ESKD patients.
Keywords: dialysate, end-stage kidney disease, implantable
cardiac device, sudden cardiac arrest, sudden cardiac death
I N T R O D U C T I O N
Sudden cardiac death (SCD) is defined as an unexpected death
due to cardiac causes in a person with known or unknown car-
diac disease, within 1 h of symptom onset (witnessed SCD) or
within 24 h of the last proof of life (unwitnessed SCD). Since
cause of death is subject to interobserver variability, there can
be misclassification of SCD [1].
SCD is a leading cause of death among the general popula-
tion, accounting for up to 15% of all deaths [2]. SCD represents
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an important cause of death in end-stage kidney disease
(ESKD) patients [3], but the precise estimate of its incidence is
difficult to establish because studies on the incidence of SCD in
ESKD are often combined with those related to sudden cardiac
arrest (SCA) occurring during a haemodialysis (HD) session.
However, extradialysis SCD and intradialysis SCA represent
different clinical situations and should be kept distinct. In fact,
the dialysis session may itself favour the onset of life-
threatening arrhythmias, beyond the clinical conditions of the
patient. Moreover, hypotension and syncope are quite common
during HD sessions and highlight a series of risk factors [4, 5].
Their occurrence requires immediate interventions of health-
care professionals for a prompt diagnosis and for differentiating
these events from SCA. The aim of the European Dialysis
(EUDIAL) Working Group was to critically review the current
literature examining the causes of extradialysis SCD and
intradialysis SCA in ESKD patients and potential management
strategies to reduce the incidence of such events.
E P I D E M I O L O G Y O F S C D A N D
I N T R A D I A L Y S I S S C A I N E S K D P A T I E N T S
In the US Renal Data System database, arrhythmia and cardiac
arrest were the single greatest cause of death, comprising 40%
of known causes of death among dialysis patients, constituting
nearly 78% of all cardiovascular causes of death [3]. Compared
with peritoneal dialysis (PD), the rate of SCD is50% higher in
HD patients 3 months after dialysis initiation, although these
rates reach parity by 2 years [3]. Although SCD accounts for a
considerable number of deaths in ESKD patients, it is somewhat
surprising that the number of such deaths during dialysis ses-
sions is not greater, considering the increased prevalence of left
ventricular hypertrophy and coronary atheromatous and arte-
riosclerotic disease in HD patients and the changes in cardiac
perfusion and electrolyte fluxes. Karnik et al. [6] reported a rate
of intradialysis SCA of 7.0/100 000 HD sessions, while Pun et al.
[7] described a rate of 4.5 per 100 000 dialysis treatments. The
incidence of such events is therefore relatively low, but the prog-
nosis after an intradialysis SCA is very poor. Karnik et al. [6]
observed that only 40% of patients were successfully resusci-
tated and were still alive after 2 days. Of the 60% who died
within 48 h of the arrest, 13% died in the dialysis unit.
P A T H O P H Y S I O L O G Y O F S C D A N D
I N T R A D I A L Y S I S S C A I N E S K D P A T I E N T S
When faced with sudden death, presumably of cardiac origin
(SCD), it is not easy to determine what arrhythmia led to death.
It may happen so that when the first electrocardiogram (ECG)
is performed it is impossible to understand whether any
recorded asystolic bradyarrhythmia is the cause of the event or
is the consequence of an episode of ventricular fibrillation (VF).
This doubt can be resolved only if a device [e.g. ECG Holter,
intracardiac device or implantable loop recorder (ILR)] was re-
cording the fatal event [8].
The rhythm most easily recorded in cardiopathic patients at
the time of SCD appears to be VF [9, 10]. However, Cobb et al.
[11] suggested that the episodes of VF represent the cause of
SCD in a smaller proportion than previously thought. It is not
clear what fatal arrhythmia is occurring in dialysis patients who
undergo SCD. Wan et al. [12] showed that 78.6% of the SCAs
occurring in 75 HD patients bearing a wearable cardioverter de-
fibrillator were due to ventricular tachycardia (VT) or VF and
only 21.4% were due to asystole. The average left ventricular
ejection fraction (LVEF) of the study population was 27.4%,
with <19% of patients having an LVEF >35%. A subsequent
study performed in HD patients with an implanted cardiac
monitor recorded eight unexpected SCDs due to severe brady-
cardia with asystole. In this population, one of the exclusion cri-
teria was the presence of LVEF <35% [13]. The idea that SCDs
may be due mainly to bradyarrhythmias has been strengthened
by two recent studies in HD patients with ILRs. Sacher et al.
[14] studied 71 HD patients (follow-up 21 months), document-
ing four SCDs in diabetic patients due to progressive bradycar-
dia followed by asystole. Three of the four subjects had an
LVEF >50% (for one of them, LVEF was not known).
Furthermore, Roy-Chaudhury et al. [15] documented 14 epi-
sodes of asystole and only one of sustained VT in a population
of 66 younger HD patients implanted with an ILR and followed
for 6 months. None of these arrhythmias were fatal. Eighty-six
percent of patients with clinically significant arrhythmia were
diabetic and their mean LVEF was 55%. Several authors have
suggested that there is a relationship between the timing of
SCDs and the dialysis session in HD patients, showing two fre-
quency peaks, one at the end of the longer interdialytic interval
(LIDI) and the second immediately after the first dialysis ses-
sion of the week [16, 17]. The study by Wong et al. [13] con-
firmed that the risk of SCD was greater during the LIDI.
Furthermore, all the events recorded by Sacher et al. [14]
occurred during the LIDI and the clinically significant arrhyth-
mias described by Roy-Chaudhury et al. [15] had the highest
frequency during the last 12 h of the LIDI. None of the de-
scribed studies could provide evidence of an association be-
tween plasma electrolyte levels and fatal events. However, the
study by Sacher et al. [14] showed that a higher risk for cardiac
conduction disorders was related to plasma potassium (Kþ)
concentration>5.0 mmol/L and a higher risk for ventricular ar-
rhythmia to a plasma Kþ concentration <4.0 mmol/L.
Epidemiological studies suggested a significant association be-
tween the values of pre-dialysis hyperkalaemia and SCD
[17, 18]. Combining all this evidence, we hypothesize that dur-
ing the first short interdialysis period of the week HD patients
suffer from a sudden decrease in plasma Kþ concentration,
whereas at the end of the LIDI they may present with marked
hyperkalaemia and acidosis. Both conditions can lead to cardiac
electrical instability, which could potentially result in life-
threatening arrhythmias (i.e. VF or bradyarrhythmia with asys-
tole). However, it is possible that other risk factors due to car-
diac comorbidities and uraemia per se may contribute to
sudden mortality in ESKD patients. In fact, PD patients, who
do not undergo rapid changes in electrolyte concentrations,
also show a high rate of SCD [19]. PD is less intense than HD:
the treatment is more or less continuous with slight variations
related to different modes of PD. Therefore it is also more
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difficult to identify a causal relationship between the actual
treatment and treatment-induced SCD. Nevertheless, the death
risk for abnormalities in plasma Kþ concentration could be
even higher in PD compared with HD patients since PD
patients are at a higher risk for hypokalaemia, a clinical situa-
tion that can lead to dangerous tachyarrhythmias [20]. A link
between SCD in PD patients with reduced LVEF and elevated
plasma levels of pro-brain natriuretic peptide (pro-BNP) and
troponin T has been shown, suggesting an important role of
heart failure and ischaemic heart disease as factors associated
with increased sudden mortality in this population [21]. Some
cardiovascular comorbidities have also been associated with
SCD in patients undergoing HD. In particular, a higher risk of
SCD in incident HD patients affected by obstructive sleep ap-
noea (OSA), after adjusting for possible confounding factors,
was shown when compared with subjects without OSA [22].
Moreover, among HD patients with severe aortic stenosis, with-
out aortic valve replacement, the risk of SCD was particularly
high [23].
In conclusion, both brady- and tachyarrhythmias may un-
derlie SCD in ESKD patients. Recent data suggest that the
former may be most frequently responsible for the fatal event
in HD patients and a relationship between SCD and dialysis
timing has been shown. Diabetic patients seem to be particu-
larly exposed to this type of death, even in the presence of a
normal LVEF and should therefore be monitored more
carefully.
More than a decade ago, Davis et al. [24] described 110 epi-
sodes of intradialysis SCA that occurred in dialysis clinics, in-
cluding 10 before, 72 during and 20 immediately after the end
of the HD session. In the majority of cases occurring during
and after the HD session, the initial recorded arrhythmia was a
VF or a VT episode (67% and 85%, respectively), whereas in the
other cases, the first monitored ECG rhythm was a pulseless
electrical activity or asystole. Only 46% of patients survived at
least 24 h after SCA and 24% were discharged alive from the
hospital. The prognosis was better for those patients whose
event was associated with tachyarrhythmia compared with bra-
dyarrhythmia [24]. It should be remembered that two-thirds of
events occurred before the routine installation of automated ex-
ternal defibrillators (AEDs) in dialysis facilities. However, even
when an AED was available, the device was applied prior to
emergency medical services (EMS) arrival in only half of those
SCA events [24].
These findings are partially in contrast to those described
in a more recent study that examined 398 cases of SCA occur-
ring at outpatient dialysis facilities [25], designed to assess the
impact of dialysis practice guidelines recommending basic life
support (BLS) training for outpatient dialysis staff and avail-
ability of AEDs in dialysis clinics [26]. Dialysis staff initiated
cardiopulmonary resuscitation (CPR) before the arrival of
EMS in 81% of events. Sixty-six percent of the SCAs presented
with a non-shockable initial monitored rhythm, and dialysis
staff applied an AED before EMS arrival in 52% of cases.
Staff-initiated AED application was more likely within larger
dialysis clinics, but there were no significant patient or cardiac
arrest characteristics associated with AED use by dialysis staff.
Almost half of the patients (48%) survived to hospital admis-
sion and only 26% of the total population was discharged alive
from the hospital. Patients on whom CPR had been initiated
directly by dialysis staff had 3 times greater survival, as well as
a favourable neurologic status upon discharge, than patients
on whom CPR was performed exclusively by EMS, but there
was no advantage to early use of the AED, presumably be-
cause only 37% of patients demonstrated a shockable arrhyth-
mia [25]. As about only half of patients with access to AEDs
had monitoring by the dialysis staff, then it is possible that in-
creased AED usage could have identified more shockable
rhythms.
Many factors influence the ability of a victim or patient to re-
ceive effective BLS prior to the arrival of EMS [25].
Measurement of time to correct AED application and shock de-
livery (in shockable rhythms) may allow the standardization of
response at outpatient dialysis facilities. In a report on the
results of public access to defibrillation for cardiac arrests (oc-
curring at home in 87% of cases), earlier intervention (in
4.8 min versus 6.2 min) was associated with a higher rate of
shockable rhythms (close to 24%) and with a tripling of survival
(from 3.3% to 10.5%) [27].
In summary, even though intradialysis SCA outcomes are
poor, outcomes are greater than those for unselected out-of-
hospital SCA, and early application of AEDs is a likely next step
for potentially improving these outcomes. Finally, it should be
noted that only 20% of unselected patients who suffer an in-
hospital cardiac arrest have a shockable rhythm and have a sur-
vival to hospital discharge of25% [28].
The incidence of intradialysis SCA is reported to be greater
during the first dialysis session of the week [6, 24]. At this time,
patients have the highest levels of plasma Kþ and metabolic aci-
dosis. A potassium dialysate (KþD) concentration <2 mmol/L
is associated with a >2-fold increase in the risk of SCA in
patients with pre-dialysis serum concentrations within the nor-
mal reference range [6, 7]. The risk of intradialysis SCA is also
doubled in patients treated with a low calcium dialysate
(Ca2þD) concentration (1.25 mmol/L) and increases in those
with a higher serum-to-Ca2þD gradient (40% for 1 mmol/L in-
crement) [29]. It is interesting to note that the association be-
tween SCA and low KþD and low Ca2þD persisted after
adjustment for a history of coronary heart disease and conges-
tive heart failure, while these traditional risk factors were not
significantly influential on SCA incidence [7]. Several studies
have shown that the HD session induces a prolongation of ven-
tricular repolarization time (expressed by the QT interval of an
ECG) inversely related to the calcium beginning-to-end plasma
gradient during the HD session [30–32]. This phenomenon is
particularly evident when both low Ca2þD (1.25 mmol/L) and
low KþD (2 mmol/L) concentrations are employed [32].
A marked prolongation of the QT interval due to sudden
intradialysis changes of plasma electrolytes could potentially in-
duce episodes of ‘torsades de point’ fibrillation. In contrast, pre-
dialysis hyperkalaemia could induce pulseless electrical activity
or asystolic events [32]. Knowledge of the patient’s electrolyte
balance can predict the necessary advanced cardiac life support
steps in the event of cardiac events.
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D I A L Y S I S T R E A T M E N T P R A C T I C E S
Dialysate potassium
The control of plasma Kþ remains a pervasive challenge in
the management of HD patients. One of the main goals of HD
is the removal of Kþ that has accumulated in the body in the in-
terval between two dialysis sessions. A correct Kþmass balance
during HD is crucial: for the vast majority of patients this
should be negative and of the same order of magnitude as the
positive interdialytic Kþ mass balance in order to prevent both
dangerous intradialysis hypokalaemia and fatal interdialysis
hyperkalaemia [33]. Indeed, some studies have shown that high
pre-dialysis Kþ concentrations are associated with an increased
risk of SCD [7, 34]. The magnitude of the plasma Kþ concentra-
tion is dependent upon dietary Kþ intake, urinary Kþ excretion
and Kþ losses in the stool, the utilization of Kþ binders, KþD
concentration, dialysate glucose and bicarbonate concentra-
tions, the efficiency of the dialyser and the duration and fre-
quency of dialysis [35]. Plasma Kþ concentration rapidly
decreases during the first 60 min and stabilizes during the last
60 min of dialysis. Plasma Kþ reaches a steady state during the
last hour of dialysis, while Kþ continues to be lost into the dialy-
sate. It can therefore be assumed that the Kþ removal rate is
equal to the intra- to extracellular mass transfer rate at these
time points [33].
The QT interval is a recognized ECG marker of the ventricu-
lar repolarization time and its prolongation has been associated
with an increased risk of SCD in both pathological and healthy
populations and also in HD patients [36–39]. Electrolyte disor-
ders are one of the main HD-related factors that can cause QT
interval alterations and cardiac arrhythmias, because of their in-
volvement in the genesis, duration, morphology and propaga-
tion of the cellular action potential. The electrolytes that mostly
influence the ventricular repolarization are Kþ and ionized
Ca2þ [40]. The Nernst equation indicates that the electrical ac-
tivity of the heart is related to the ratio of the intracellular and
extracellular Kþ levels. Using a lower KþD concentration, one
removes Kþ mainly from the extracellular space and very little
from the intracellular one. Surprisingly, most patients are able
to tolerate the intradialysis hyperpolarization of the cardiac
muscle membrane potential, induced by an increase in the in-
tracellular: extracellular Kþ ratio brought about by a reduction
in the extracellular Kþ value as a result of dialysis. The fre-
quency of arrhythmias is greater during the last 2 h of dialysis
and immediately post-dialysis [32]. Kþ modelling, first sug-
gested by Redaelli et al. [41], involves decreasing the KþD con-
centration exponentially to maintain a constant plasma–KþD
gradient of 1.5 mmol/L. Santoro et al. [42] observed greater
arrhythmogenic activity with the use of a constant and relatively
low KþD concentration compared with decreasing Kþ profiling
in dialysis-sensitive arrhythmic patients.
Given the above, there is no good evidence that intradialysis
ventricular arrhythmias are associated with an increased risk of
overall mortality or sudden mortality [43, 44] or that the use of
dialysis modalities with a profiled KþD improves clinical out-
comes. However, higher Kþ gradients (serum Kþ concentra-
tion–KþD concentration) are independently associated with a
greater risk of all-cause hospitalizations and emergency depart-
ment visits [45]. In addition, a low KþD concentration
(<2 mmol/L) is associated with an increased incidence of intra-
dialysis SCA [7] and extradialysis SCD compared with a KþD
concentration>3 mmol/L [18].
In conclusion, the true challenge in HD patients is to avoid
both life-threatening pre-dialysis hyperkalaemia (plasma Kþ
level>6 mmol/L) and post-dialysis relative hypokalaemia (or at
least a very rapid decrease of plasma Kþ concentration and the
related risk of lethal arrhythmias). Resins (calcium or sodium
polystyrene sulphonate) may be used; although Kþ-binding
sodium-based resins have been prescribed for 50 years, there
have been no large studies of their effects among HD patients
[46]. Newer Kþ binding medications are currently available
that could help to reduce the incidence of pre-dialysis hyperka-
laemia [47, 48]. Although possibly less acceptable to patients, al-
ternative dialysis strategies, such as longer or more frequent
HD sessions, may be required to control hyperkalaemia.
Dialysate calcium
In the last decade there has been a shift in Ca2þD prescrip-
tion down from 1.75 to 1.25 mmol/L [49]. A lower Ca2þD con-
centration may induce an increase in myocardial repolarization
time and QT interval [30, 32]. Lower Ca2þD concentrations are
also associated with a higher risk of intradialysis SCA [29]. The
prescription of an individualized Ca2þD concentration for HD
patients requires an integrated quantitative assessment of bone
mineral metabolism and of cardiovascular status. When choos-
ing a Ca2þD concentration, the impact on calcium balance and
the change in serum calcium levels must be considered, with
the awareness that these two aims might not necessarily be
achieved at the same time [49].
In conclusion, a low Ca2þD concentration should be avoided
in patients presenting with prolonged basal QT interval and
should not be used in combination with a lower KþD concen-
tration. The Ca2þD concentration should be designed so as not
to lower serum Ca2þ, especially in patients at risk of hypokalae-
mia at the end of the dialysis session.
Dialysate bicarbonates
The main potential adverse effects associated with a high di-
alysate bicarbonate (DBIC) concentration are increased carbon
dioxide formation, electrolyte imbalances and QT prolongation
[50]. During HD, an increase in serum bicarbonate levels leads
to a decrease in serum Ca2þ concentration. This phenomenon
is primarily caused by an alkalosis-induced change in the elec-
trical charge of proteins, which increases the amount of com-
plexed calcium. A correction of metabolic acidosis that is too
rapid can then compromise vascular and cardiac contraction
due to the decrease in Ca2þ [51]. Furthermore, Fissell and
Hakim [52] emphasized that dialysis treatment lowers plasma
Kþ, both by removal of Kþ into the dialysate and also by a rapid
shift of Kþ from the extracellular into the intracellular space, as
metabolic acidosis is corrected. Moreover, a randomized con-
trolled trial (RCT) reported an association between higher DBIC
concentration and a faster decrease in intradialysis plasma Kþ
concentrations [53]. When higher DBIC concentrations are
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employed, the combination of a sudden decrease in plasma
Ca2þ and Kþ induced by metabolic alkalosis could lead to dan-
gerous prolongation of ventricular repolarization time. An RCT
observed a prolongation of the QT interval in association with
high DBIC, low K
þD and low Ca2þD concentrations [54]. This
association was an independent predictor of prolongation of
the QT interval [39].
In summary, individualizing the treatment to the patient is
important to correct metabolic acidosis while avoiding symp-
toms of transient secondary metabolic alkalosis and potential
harm. High DBIC concentrations may lead to sudden reductions
in plasma concentrations of both Kþ and Ca2þ. This phenome-
non causes an increase in ventricular repolarization time and
prolongation of the QT interval, potentially increasing the risk
for life-threatening arrhythmias. It is therefore advisable not to
combine lower Ca2þD and KþD concentrations with high DBIC
concentrations, particularly in patients with a prolonged basal
QT interval.
Dialysate magnesium
An electrolyte that has received little attention is magnesium.
A large observational study from Japan using data from 142 555
HD patients reported a J-shaped curve between magnesium
concentrations and all-cause mortality (both cardiovascular
and non-cardiovascular) [55]. Moreover, it has been shown
that serum magnesium concentrations are independently and
inversely associated with all-cause mortality, cardiovascular
mortality and sudden death in European HD patients [56].
Future magnesium research should address dialysate selec-
tion specific to magnesium concentrations (the standard dialy-
sates contain 0.5 mmol/L and serum magnesium typically
decreases during dialysis, which can be affected by citrate-
containing dialysates and higher DBIC concentrations) [57] and
the potential role in electrophysiologic abnormalities in the HD
population. These steps may allow future tailoring of the dialy-
sate specific to cardiac arrhythmias and SCD and SCA.
Ultrafiltration
An ultrafiltration volume>5.7% of body weight has been re-
lated to a higher risk for SCD {hazard ratio [HR] 1.13 [95% con-
fidence interval (CI) 1.00–1.27]; P¼ 0.04} [18]. Moreover, Pun
et al. [7] found an association between intradialysis SCA and
percent volume removed during the dialysis session [odds ratio
(OR) 1.11 (95% CI 1.02–1.20); P¼ 0.011]. However, more data
are needed to prove that an excessive ultrafiltration volume has
a causal relationship with the incidence of sudden mortality in
HD patients.
P R E V E N T I O N T O O L S — D R U G S
A paucity of evidence exists regarding the role of cardiovascular
drugs in the prevention of SCA in HD patients. This is mainly
due to commonly excluding HD patients in RCTs. Below is a
summary regarding the efficacy and safety of drugs acting on
the electrophysiological properties of the heart and/or on the
sympatho-vagal regulation of the heart and vessels with regard
to the specific setting of HD patients.
b-blockers
Conflicting results regarding the efficacy and safety of b-
blockers in HD patients have been found. For example, a sys-
tematic review included three RCTs that found a significant risk
reduction for b-blockers in cardiovascular mortality and car-
diovascular events, but also nine observational studies that did
not find any effect in these outcomes [58]. In contrast, in three
other observational studies, b-blockers were associated with a
lower risk for SCD in HD patients [18] or a reduction in all-
cause mortality [59, 60]. In another RCT, including 114 HD
patients, a significant reduction in all-cause and cardiovascular
mortality, yet no statistically significant reduction in SCD, was
found for the patients treated with carvedilol [61]. In a post hoc
analysis of the Hemodialysis Study, including 1747 patients, no
association between b-blocker intake and SCD was found [62].
Angiotensin-converting enzyme inhibitors (ACEis)/
angiotensin receptor blockers (ARBs)
So far, no convincing data on the benefit of ACEis or ARBs
for preventing SCD in HD patients has been found. No signifi-
cant reduction in the risk of cardiovascular events in the treat-
ment group with an ACEi or ARB was found in a systematic
review [63]. For example, RCTs on fosinopril and olmesartan
have both failed to demonstrate a reduction in the risk of car-
diovascular events or all-cause mortality in HD patients [64,
65]. Similarly, in another study, the risk of SCD was not statisti-
cally significantly reduced for the HD patients treated with spi-
ronolactone [66]. However, in two observational studies, a
reduction in cardiovascular mortality or overall mortality was
found for HD patients treated with an ACEi [67, 68].
Potassium binding agents
Sodium polystyrene sulphonate and calcium polystyrene
sulphonate are commonly used in the general population to
treat chronic hyperkalaemia [48, 69], however, contradicting
effects of fludrocortisone or sodium zirconium cyclosilicate
(ZS-9) on plasma Kþ levels in HD patients have been found
[70–72]. In these two RCTs, outcomes associated with SCD and
cardiovascular mortality were not reported [48, 69].
Calcium channel blockers (CCBs)
In an observational study, a beneficial, although not statisti-
cally significant, effect of CCBs for HD patients was found on
death at 24 h after SCA [73]. Similarly, in another observational
study including 4065 HD patients, the use of CCBs was associ-
ated with a 23% lower risk of cardiovascular mortality [74].
Calcimimetics
In the Cochrane review of Ballinger et al. [75], including 18
studies with 7446 participants, no effect on all-cause or cardio-
vascular mortality was found for patients treated with cinacal-
cet. SCD was not included as an outcome in this review and was
only investigated in one study, in which no differences in SCD
were found between cinacalcet and usual care [76].
Etelcalcetide, which was compared with placebo in two RCTs,
significantly reduced parathyroid hormone levels; however,
hypocalcaemia was more common in the etelcalcetide group
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and led to prolongation of QT intervals in many patients. No
mortality or cardiovascular outcomes were reported [77].
Amiodarone
Amiodarone exerts many electrophysiological effects and is
widely used for both atrial and ventricular tachyarrhythmias,
despite the risk of adverse effects (on the thyroid gland, lungs
and liver). However, there have been no consistent findings re-
garding its effectiveness in preventing SCD in HD patients. In
an analysis of Dialysis Outcomes and Practice Patterns Study
(DOPPS) amiodarone was associated with a higher risk for
SCD in HD patients [HR 1.44 (95% CI 1.16–1.81)] [18], how-
ever, as for any observational study, no conclusion on causality
can be drawn. In a Cochrane systematic review [78] including
24 studies, amiodarone was associated with a significant reduc-
tion in the risk of SCD, cardiac and all-cause mortality for per-
sons at high risk (primary prevention) or who have recovered
from an SCA (secondary prevention), however, no specific sub-
groups of ESKD or HD patients were included in these studies.
Digoxin
In a retrospective observational cohort study including
120 864 incident HD patients, digoxin use was associated with a
28% increased risk of death and the increase in mortality risk
was most pronounced in patients with lower pre-dialysis serum
Kþ levels [79].
In conclusion, contradicting and limited evidence have been
found on the efficacy and safety of anti-arrhythmic drugs for
HD patients in terms of SCD or fatal cardiovascular events. In
addition, poor long-term adherence to drug therapy is found in
dialysis patients [80, 81], which might limit the validity of the
findings to daily clinical practice. Therefore no strong recom-
mendations in favour of any specific medication or type of
medication can be made and large high-quality RCTs in HD
patients are needed.
P R E V E N T I O N T O O L S — I M P L A N T A B L E
C A R D I O V E R T E R D E F I B R I L L A T O R S ( I C D s )
Guidelines for sudden death prevention published by the main
cardiology associations recommend implanting an implantable
cardioverter defibrillator (ICD) in primary prevention in
patients with LVEF <35% and with a life expectancy of at least
1 year and, in the setting of secondary prevention, in patients
with documented VF or haemodynamically not tolerated VT in
the absence of reversible causes [82]. However, the presence of
ESKD was an exclusion criterion in the RCTs that demon-
strated that the ICD confers a survival benefit in populations
with a high risk of SCD [83–85]. Several observational studies
have shown that, in patients implanted with an ICD in primary
prevention, the presence of ESKD constitutes a negative prog-
nostic factor in terms of mortality [86–88]. However, when
populations of dialysis patients with indication for ICD implan-
tation are compared, data are not consistent. Hiremath et al.
[89], in an observational study collecting data from two regis-
tries, showed that an ICD implant is associated with better sur-
vival in ESKD patients with ventricular dysfunction (LVEF
<35%) when compared with patients not implanted with the
device [HR 0.40 (95% CI 0.19–0.82)] [89]. The risk of bias and
unmeasured confounding obviously constitutes an important
limitation and propensity score matching can be employed for
reducing this risk. Indeed, Pun et al. [90], comparing two pro-
pensity-matched cohorts of ESKD patients, one that received
an ICD in primary prevention and the other without ICD, did
not observe differences in mortality in the two groups (43.4% in
the ICD cohort versus 39.7% in the control group). The uncer-
tainty about evidence leads to the fact that only a minority of
ESKD patients with an indication for ICD implantation actually
receive the device. In an Italian population of 2072 ESKD
patients (154 of them having an LVEF <35%), only 52 (33%)
were implanted with an ICD. As expected, mortality was higher
in patients with an ICD indication than in those without [HR
1.59 (95% CI 1.06–2.38)], but subjects with ventricular dysfunc-
tion and without an ICD implant had the worst prognosis [HR
2.67 (95% CI 2.09–3.39)]. The rate of SCD was higher not only
in patients with an ICD indication, but also patients without an
ICD indication had a high incidence of SCD [91]. The high in-
cidence of SCD in dialysis patients with preserved LVEF is the
rationale of the only RCT so far performed in this population,
the ICD2 trial [92]. This very recent study is particularly inter-
esting because the presence of LVEF <35% was an exclusion
criterion, thus leading to an RCT exploring a new indication for
ICD implantation in the specific setting of dialysis patients. The
study tried to answer the question whether ESKD per se is a risk
factor for SCD, independent of a low ejection fraction, and if
this risk can be minimized by ICD implantation. Indeed,
patients who, according to the guidelines, would have a classical
indication for ICD implantation for primary prevention of
SCD, on the basis of a depressed ejection fraction, were not
recruited. The trial was stopped, as per the recommendation of
the data and safety monitoring board, for futility reasons (i.e. in-
ability of the RCT to achieve its original objectives) after inclu-
sion of 188 patients of the 200 planned, 97 in the ICD group and
91 in the control group. The median duration of follow-up was
6.8 years. The 5-year mortality rate was high and similar in the
two groups (50.6% in the ICD group versus 54.5% in the control
group). The cumulative incidence of SCD was 9.7% in the ICD
group versus 7.9% in the control group [HR 1.32 (95% CI 0.53–
3.29)] [92]. The reasons for the failure of the ICD strategy to re-
duce total and sudden mortality may be several: first of all, we
must consider the possibility of a failure of the device linked to
the presence of non-shockable rhythms (asystole/pulseless elec-
trical activity) or of an arrhythmia arising in a setting of hyperka-
laemia and/or severe disorders of the acid–base balance [13, 93],
leading to ineffective termination by ICD shocks or immediate
reinitiation after shock delivery. Only post-mortem analysis of
the intracardiac ECGs (actually planned in the design of the
ICD2 trial) was able to clarify what arrhythmia was associated
with SCD. It is important to underline that the rate of device-
related adverse events was very high (27.5%) [92]. They were di-
rectly related to the ICD implantation procedure (haematoma or
infection) or were due to lead dysfunction. ICD explantation was
necessary in 7.5% of cases, mostly because of bacteraemia [92].
The outcome of patients implanted with an ICD appears more
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convincing in the clinical setting of secondary prevention.
Herzog et al. [94] retrospectively analysed a population of 6042
dialysis patients hospitalized for VF/cardiac arrest, discharged
alive and surviving at least 30 days from admission. Only 7.6% of
these patients had an ICD implantation. The latter was indepen-
dently associated with a 42% reduction in death risk [HR 0.58
(95% CI 0.50–0.66)] [94]. Charytan et al. [95] showed in a popu-
lation of 9528 dialysis patients who received an ICD for second-
ary prevention between 1994 and 2006 an overall 14% (95% CI
9–19) lower mortality risk compared with propensity-matched
controls [95].
An important problem is the high rate of complications as-
sociated with ICD implantation in dialysis patients. A meta-
analysis showed a significant increase in infectious complica-
tions associated with the presence of ESKD [HR 8.73 (95% CI
3.42–22.31)] [96]. Infections of the ICD system require com-
plete removal of the implanted system, a procedure associated
with inherent risk and complications [97]. Other frequent com-
plications are those related to lead dislodgement requiring revi-
sion, lead dysfunction requiring extraction, bleeding and
venous thrombosis [92, 98, 99]. It has been suggested that the
use of subcutaneous ICDs may be an advantage for reducing
the risk of central venous stenosis and infection compared with
an endocardial ICD with transvenous leads, but this kind of de-
vice may not be useful in case of severe bradyarrhythmias [100].
In general, the decision to implant an ICD in the setting of
ESKD and dialysis is clinically challenging and should require
an interdisciplinary approach, with strict collaboration between
nephrologists and cardiologists, targeted to assess in the indi-
vidual case the risk–benefit of every specific treatment option
[97]. Clinical decision making may be even more difficult in
case of life-threatening ventricular tachyarrhythmias that ap-
pear to be facilitated by transient but not entirely correctable
causes [101].
In a clinical perspective, the challenge in decision making
about ICD implantation is that, given the substantial
comorbidities that frequently exist in ESKD patients, the benefit
of ICD therapy may be attenuated due to the competing causes
for death. This important issue may also be associated with a se-
ries of factors, including electrolyte imbalances, that increase
the risk of ineffective shock therapy or onset of non-shockable
rhythms (asystole/pulseless electrical activity) as the pathophys-
iological mechanism of arrhythmic SCD (Figure 1).
C O N C L U S I O N S
SCD remains a major cause of death in the ESKD population,
despite the efforts made in recent years to prevent it and to
identify patients at greater risk. Regarding the problem, numeri-
cally less relevant, of patients affected by intradialysis SCA,
some modifiable risk factors have been identified, such as low
KþD and Ca2þD concentrations, and some advantages linked
to the presence of AEDs in dialysis units have been docu-
mented. However, it must be recognized that the arrhythmia
determining the fatal event is not always shockable. The prob-
lem of extradialysis SCD is more complex and its causes remain
partly unknown. A reduced LVEF associated with SCD is pre-
sent only in a minority of cases occurring in HD patients. This
demonstrates that SCD occurs with different characteristics in
ESKD compared with patients with ischaemic heart disease
and/or heart failure and not affected by ESKD. Recent evidence
suggests that in this population, bradyarrhythmias may repre-
sent the fatal arrhythmia more frequently than tachyarrhyth-
mias. This fact may partly explain why several studies could not
demonstrate an advantage of ICDs in preventing SCD in ESKD
patients. Electrolyte imbalances, frequently present in HD
patients, could explain part of the arrhythmic phenomena, as
suggested by the relationship between SCD and timing of the
FIGURE 1: It shows the arrhythmias potentially leading to SCD and the role of ICD therapy.
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HD session. However, the high incidence of SCD in PD patients
suggests that other factors are also involved in determining sud-
den mortality in the uraemic patient.
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32. Genovesi S, Dossi C, Viganò MR et al. Electrolyte concentration during
haemodialysis and QT interval prolongation in uraemic patients. Europace
2008; 10: 771–777
33. Basile C, Libutti P, Lisi P et al. Ranking of factors determining potassium
mass balance in bicarbonate haemodialysis. Nephrol Dial Transplant 2015;
30: 505–513
34. Karaboyas A, Zee J, Brunelli SM et al. Dialysate potassium, serum potas-
sium, mortality, and arrhythmia events in hemodialysis: results from the
Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis
2017; 69: 266–277
35. Sam R, Vaseemuddin M, Leong WH et al. Composition and clinical use of
hemodialysates. Hemodial Int 2006; 10: 15–28
36. Algra A, Tijssen JGP, Roelandt J et al. QTc prolongation measured by stan-
dard 12-lead electrocardiography is an independent risk factor for sudden
death due to cardiac arrest. Circulation 1991; 83: 1888–1894
37. Montanez A, Ruskin JN, Hebert PR et al. Prolonged QTc interval and risks
of total and cardiovascular mortality and sudden death in the general pop-
ulation: a review and qualitative overview of the prospective cohort studies.
Arch Intern Med 2004; 164: 943–948
38. Zhang Y, Post WS, Blasco-Colmenares E et al. Electrocardiographic
QT interval and mortality: a meta-analysis. Epidemiology 2011; 22:
660–670
39. Genovesi S, Rossi E, Nava M et al. A case series of chronic haemodialysis
patients: mortality, sudden death, and QT interval. Europace 2013; 15:
1025–1033
40. Severi S, Grandi E, Pes C et al. Calcium and potassium changes during
haemodialysis alter ventricular repolarization duration: in vivo and in sil-
ico analysis. Nephrol Dial Transplant 2007; 23: 1378–1386
41. Redaelli B, Locatelli F, Limido A et al. Effect of a new model of hemodialy-
sis potassium removal on the control of ventricular arrhytmias. Kidney Int
1996; 50: 609–617
42. Santoro A, Mancini E, London G et al. Patients with complex arrhytmias
during and after haemodialysis suffer from different regimens of potas-
sium removal. Nephrol Dial Transplant 2007; 23: 1415–1421







niversite de Bordeaux user on 16 D
ecem
ber 2021
43. Multicentre, cross-sectional study of ventricular arrhythmias in chronically
haemodialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari.
Lancet 1988; 2: 305–309
44. Sforzini S, Latini R, Mingardi G et al. Ventricular arrhythmias and four-
year mortality in haemodialysis patients. Lancet 1992; 339: 212–213
45. Brunelli SM, Spiegel DM, Du Mond C et al. Serum-to-dialysate potassium
gradient and its association with short-term outcomes in hemodialysis
patients. Nephrol Dial Transplant 2018; 33: 1207–1214
46. Jadoul M, Karaboyas A, Goodkin DA et al. Potassium-binding resins: asso-
ciations with serum chemistries and interdialytic weight gain in hemodial-
ysis patients. Am J Nephrol 2014; 39: 252–259
47. Weir MR, Bakris GL, Bushinsky DA et al. Patiromer in patients with kid-
ney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med
2015; 372: 211–221
48. Packham DK, Rasmussen HS, Lavin PT et al. Sodium zirconium cyclosili-
cate in hyperkalemia. N Engl J Med 2015; 372: 222–231
49. Basile C, Libutti P, Di Turo L et al. Effect of dialysate calcium concentra-
tion on parathyroid hormone and calcium balance during a single dialysis
session using bicarbonate hemodialysis: a crossover clinical trial. Am J
Kidney Dis 2012; 59: 92–101
50. Basile C, Rossi L, Lomonte C. Dialysate bicarbonate concentration: too
much of a good thing? Semin Dial 2018; 31: 576–582
51. van Kuijk WH, Mulder AW, Peels CH et al. Influence of changes in ion-
ized calcium on cardiovascular reactivity during hemodialysis. Clin
Nephrol 1997; 47: 190–196
52. Fissell R, Hakim RM. Improving outcomes by changing hemodialysis
practice patterns. Curr Opin Nephrol Hypertens 2013; 22: 675–680
53. Heguilén RM, Sciurano C, Bellusci AD et al. The faster potassium-
lowering effect of high dialysate bicarbonate concentrations in chronic
haemodialysis patients. Nephrol Dial Transplant 2005; 20: 591–597
54. Di Iorio B, Torraca S, Piscopo C et al. Dialysate bath and QTc interval in
patients on chronic maintenance hemodialysis: pilot study of single dialysis
effects. J Nephrol 2012; 25: 653–660
55. Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant pre-
dictor of cardiovascular and non-cardiovascular mortality in patients un-
dergoing hemodialysis. Kidney Int 2014; 85: 174–181
56. de Roij van Zuijdewijn CL, Grooteman MP, Bots ML et al. Serum magne-
sium and sudden death in european hemodialysis patients. PLoS One
2015; 10: e0143104
57. Tangvoraphonkchai K, Davenport A. Magnesium and cardiovascular dis-
ease. Adv Chronic Kidney Dis 2018; 25: 251–260
58. Jin J, Guo X, Yu Q. Effects of beta-blockers on cardiovascular events and
mortality in dialysis patients: a systematic review and meta-analysis. Blood
Purif 2019; 48: 51–59
59. Nakao K, Makino H, Morita S et al. Beta-blocker prescription and out-
comes in hemodialysis patients from the Japan Dialysis Outcomes and
Practice Patterns Study. Nephron Clin Pract 2009; 113: c132–c139
60. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality
in United States hemodialysis patients: USRDS Waves 3 and 4 Study.
Kidney Int 2002; 62: 1784–1790
61. Cice G, Ferrara L, D’Andrea A et al. Carvedilol increases two-year surviva-
lin dialysis patients with dilated cardiomyopathy: a prospective, placebo-
controlled trial. J Am Coll Cardiol 2003; 41: 1438–1444
62. Tangri N, Shastri S, Tighiouart H et al. b-blockers for prevention of sud-
den cardiac death in patients on hemodialysis: a propensity score analysis
of the HEMO Study. Am J Kidney Dis 2011; 58: 939–945
63. Tai DJ, Lim TW, James MT et al. Cardiovascular effects of angiotensin
converting enzyme inhibition or angiotensin receptor blockade in hemodi-
alysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5: 623–630
64. Iseki K, Arima H, Kohagura K et al. Effects of angiotensin receptor block-
ade (ARB) on mortality and cardiovascular outcomes in patients with
long-term haemodialysis: a randomized controlled trial. Nephrol Dial
Transplant 2013; 28: 1579–1589
65. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in
end-stage renal disease: results of a randomized trial of fosinopril and
implications for future studies. Kidney Int 2006; 70: 1318–1324
66. Matsumoto Y, Mori Y, Kageyama S et al. Spironolactone reduces cardio-
vascular and cerebrovascular morbidity and mortality in hemodialysis
patients. J Am Coll Cardiol 2014; 63: 528–536
67. Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of he-
modialysis patients. Am J Kidney Dis 2002; 40: 1023–1029
68. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and
angiotensin-converting enzyme inhibitor therapy in patients with end-
stage renal disease and an acute myocardial infarction. J Am Coll Cardiol
2003; 42: 201–218
69. Kosiborod M, Rasmussen HS, Lavin P et al. Effect of sodium zirconium
cyclosilicate on potassium lowering for 28 days among outpatients with
hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014;
312: 2223–2233
70. Singhal PC, Desroches L, Mattana J et al. Mineralocorticoid therapy lowers
serum potassium in patients with end-stage renal disease. Am J Nephrol
1993; 13: 138–141
71. Kaisar MO, Wiggins KJ, Sturtevant JM et al. A randomized controlled trial
of fludrocortisone for the treatment of hyperkalemia in hemodialysis
patients. Am J Kidney Dis 2006; 47: 809–814
72. Ash SR, Singh B, Lavin PT et al. A phase 2 study on the treatment of
hyperkalemia in patients with chronic kidney disease suggests that the se-
lective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015; 88:
404–411
73. Pun PH, Lehrich RW, Smith SR et al. Predictors of survival after cardiac
arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2:
491–500
74. Kestenbaum B, Gillen DL, Sherrard DJ et al. Calcium channel blocker use
and mortality among patients with end-stage renal disease. Kidney Int
2002; 61: 2157–2164
75. Ballinger AE, Palmer SC, Nistor I et al. Calcimimetics for secondary hyper-
parathyroidism in chronic kidney disease patients. Cochrane Database Syst
Rev 2014; 12: CD006254
76. Messa P, Macário F, Yaqoob M et al. The OPTIMA study: assessing a new
cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyper-
parathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45
77. Block GA, Bushinsky DA, Cunningham J et al. Effect of etelcalcetide vs
placebo on serum parathyroid hormone in patients receiving hemodialysis
with secondary hyperparathyroidism: two randomized clinical trials.
JAMA 2017; 317: 146–155
78. Claro JC, Candia R, Rada G et al. Amiodarone versus other pharmacologi-
cal interventions for prevention of sudden cardiac death. Cochrane
Database Syst Rev 2015; 12: CD008093
79. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in
ESRD. J Am Soc Nephrol 2010; 21: 1550–1559
80. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphos-
phatemia, and quality of life in maintenance dialysis patients. Clin J Am
Soc Nephrol 2009; 4: 1089–1096
81. Burnier M, Pruijm M, Wuerzner G et al. Drug adherence in chronic
kidney diseases and dialysis. Nephrol Dial Transplant 2015; 30:
39–44
82. Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC guidelines
for the management of patients with ventricular arrhythmias and the pre-
vention of sudden cardiac death. Europace 2015; 17: 1601–1687
83. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted
defibrillator in patients with coronary disease at high risk for ventricular
arrhythmia. Multicenter Automatic Defibrillator Implantation Trial
Investigators. N Engl J Med 1996; 335: 1933–1940
84. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibril-
lator in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med 2002; 346: 877–883
85. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardi-
overter defibrillator for congestive heart failure. N Engl J Med 2005; 352:
225–237
86. Khan F, Adelstein E, Saba S. Implantable cardioverter defibrillators confer
survival benefit in patients with renal insufficiency but not in dialysis-
dependent patients. J Interv Card Electrophysiol 2010; 28: 117–123
87. Paul L, Hess PL, Hellkamp AS et al. Survival after primary prevention im-
plantable cardioverter-defibrillator placement among patients with chronic
kidney disease. Circ Arrhythm Electrophysiol 2014; 7: 793–799
88. Turakhia MP, Varosy PD, Lee K et al. Impact of renal function on survival
in patients with implantable cardioverter-defibrillators. Pacing Clin Electro
physiol 2007; 30: 377–384







niversite de Bordeaux user on 16 D
ecem
ber 2021
89. Hiremath S, Punnam SR, Brar SS et al. Implantable defibrillators improve
survival in end-stage renal disease: results from a multi-center registry. Am
J Nephrol 2010; 32: 305–310
90. Pun PH, Hellkamp AS, Sanders GD et al. Primary prevention implantable
cardioverter defibrillators in end-stage kidney disease patients on dialysis:
a matched cohort study. Nephrol Dial Transplant 2015; 30: 829–835
91. Genovesi S, Porcu L, Luise MC et al. Mortality, sudden death and indica-
tion for cardioverter defibrillator implantation in a dialysis population. Int
J Cardiol 2015; 186: 170–177
92. Jukema JW, Timal RJ, Rotmans JI et al. Prophylactic use of implantable
cardioverter-defibrillators in the prevention of sudden cardiac death in di-
alysis patients. Circulation 2019; 139: 2628–2638
93. Hsu JC, Marcus GM, Al-Khatib SM et al. Predictors of an inadequate defi-
brillation safety margin at ICD implantation: insights from the National
Cardiovascular Data Registry. J Am Coll Cardiol 2014; 64: 256–264
94. Herzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after car-
diac arrest and the impact of implantable cardioverter defibrillators.
Kidney Int 2005; 68: 818–825
95. Charytan DM, Patrick AR, Liu J et al. Trends in the use and outcomes of
implantable cardioverter-defibrillators in patients undergoing dialysis in
the United States. Am J Kidney Dis 2011; 58: 409–417
96. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac im-
plantable electronic device infection: a systematic review and meta-analy-
sis. Europace 2015; 17: 767–777
97. Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients
with cardiac rhythm disturbances or implantable electrical devices: clinical
significance and implications for decision making–a position paper of the
European Heart Rhythm Association endorsed by the Heart Rhythm
Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17:
1169–1196
98. Dasgupta A, Montalvo J, Medendorp S et al. Increased complication rates
of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis
2007; 49: 656–663
99. Tompkins C, Mclean R, Cheng A et al. End-stage renal disease predicts
complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol
2011; 22: 1099–1104
100. Dhamija RK, Tan H, Philbin E et al. Subcutaneous implantable cardi-
overter defibrillator for dialysis patients: a strategy to reduce central vein
stenoses and infections. Am J Kidney Dis 2015; 66: 154–158
101. Boriani G, Fauchier L, Aguinaga L et al. European Heart Rhythm
Association (EHRA) consensus document on management of arrhythmias
and cardiac electronic devices in the critically ill and post-surgery patient,
endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm
Society (APHRS), Cardiac Arrhythmia Society of Southern Africa
(CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace
2019; 21: 7–8
Received: 12.7.2019; Editorial decision: 1.8.2019
Nephrol Dial Transplant (2021) 36: 405–412
doi: 10.1093/ndt/gfz196
Advance Access publication 17 October 2019
Phosphate and bone fracture risk in chronic kidney disease
patients
Maria Fusaro1,2, Rachel Holden3, Charmaine Lok4, Giorgio Iervasi1, Mario Plebani5, Andrea Aghi6,
Maurizio Gallieni 7,* and Mario Cozzolino 8,*
1National Research Council, Institute of Clinical Physiology, Pisa, Italy, 2Department of Medicine, University of Padova, Padova, Italy,
3Department of Medicine, Division of Nephrology, Queen’s University, Kingston, Ontario, Canada, 4Department of Medicine, Division of
Nephrology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada, 5Department of
Medicine, Laboratory Medicine Unit, University of Padova, Padova, Italy, 6Department of Medicine, Clinica Medica 1, University of Padova,
Padova, Italy, 7Department of Biomedical and Clinical Sciences ‘L. Sacco’, Nephrology and Dialysis Unit, ASST Fatebenefratelli-Sacco, Università
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A B S T R A C T
In chronic kidney disease (CKD), phosphate homoeostasis
plays a central role in the development of mineral and bone dis-
order (MBD) together with decreased serum calcium and ele-
vated serum parathyroid hormone, fibroblast growth factor 23
and sclerostin levels. Today there are only a few data exploring
the direct role of abnormal phosphate homoeostasis and hyper-
phosphataemia in the development of CKD-MBD. On the other
hand, several studies have looked at the link between hyper-
phosphataemia and cardiovascular morbidity and mortality in
CKD, but there is a lack of evidence to indicate that lowering
phosphate levels improves cardiovascular outcomes in this
population. Furthermore, the impact of liberalizing phosphate
targets on CKD-MBD progression and bone fracture is cur-
rently not known. In this review we discuss the central
role of phosphate in the pathogenesis of CKD-MBD and how
it may be associated with fracture risk, both in hyper- and
hypophosphataemia.
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